tetano
Editor, Senior Moderator
Vaccine
. 2024 Jun 24:S0264-410X(24)00713-8.
doi: 10.1016/j.vaccine.2024.06.040. Online ahead of print. Winter 2022-23 influenza vaccine effectiveness against influenza-related hospitalised aLRTD: A test-negative, case-control study
Anastasia Chatzilena[SUP] 1 [/SUP], Catherine Hyams[SUP] 2 [/SUP], Rob Challen[SUP] 1 [/SUP], Robin Marlow[SUP] 2 [/SUP], Jade King[SUP] 3 [/SUP], Serena McGuinness[SUP] 2 [/SUP], Nick Maskell[SUP] 4 [/SUP], Jennifer Oliver[SUP] 2 [/SUP], Adam Finn[SUP] 2 [/SUP], Leon Danon[SUP] 5 [/SUP]; AvonCAP Research Group
Affiliations
PubMed Disclaimer
Conflict of interest statement
Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Catherine Hyams reports financial support was provided by Pfizer Inc. Adam Finn reports financial support was provided by Pfizer. Adam Finn reports a relationship with Joint Committee on Vaccination and Immunization that includes: board membership. CH is Principal Investigator of the AvonCAP study which is an investigator-led University of Bristol study funded by Pfizer and has previously received support from the NIHR in an Academic Clinical Fellowship. JO and LD are Co-Investigators on the AvonCAP Study. AF is a member of the Joint Committee on Vaccination and Immunization (JCVI) and, until December 2022 was chair of the World Health Organization European Technical Advisory Group of Experts on Immunization (ETAGE) committee. In addition to receiving funding from Pfizer as Chief Investigator of this study, he leads another project investigating transmission of respiratory bacteria in families jointly funded by Pfizer and the Gates Foundation. The other authors have no relevant conflicts of interest to declare. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
. 2024 Jun 24:S0264-410X(24)00713-8.
doi: 10.1016/j.vaccine.2024.06.040. Online ahead of print. Winter 2022-23 influenza vaccine effectiveness against influenza-related hospitalised aLRTD: A test-negative, case-control study
Anastasia Chatzilena[SUP] 1 [/SUP], Catherine Hyams[SUP] 2 [/SUP], Rob Challen[SUP] 1 [/SUP], Robin Marlow[SUP] 2 [/SUP], Jade King[SUP] 3 [/SUP], Serena McGuinness[SUP] 2 [/SUP], Nick Maskell[SUP] 4 [/SUP], Jennifer Oliver[SUP] 2 [/SUP], Adam Finn[SUP] 2 [/SUP], Leon Danon[SUP] 5 [/SUP]; AvonCAP Research Group
Affiliations
- PMID: 38918104
- DOI: 10.1016/j.vaccine.2024.06.040
PubMed Disclaimer
Conflict of interest statement
Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Catherine Hyams reports financial support was provided by Pfizer Inc. Adam Finn reports financial support was provided by Pfizer. Adam Finn reports a relationship with Joint Committee on Vaccination and Immunization that includes: board membership. CH is Principal Investigator of the AvonCAP study which is an investigator-led University of Bristol study funded by Pfizer and has previously received support from the NIHR in an Academic Clinical Fellowship. JO and LD are Co-Investigators on the AvonCAP Study. AF is a member of the Joint Committee on Vaccination and Immunization (JCVI) and, until December 2022 was chair of the World Health Organization European Technical Advisory Group of Experts on Immunization (ETAGE) committee. In addition to receiving funding from Pfizer as Chief Investigator of this study, he leads another project investigating transmission of respiratory bacteria in families jointly funded by Pfizer and the Gates Foundation. The other authors have no relevant conflicts of interest to declare. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.